Nordic Bioscience A/S, a Danish company and world leader in biomarker development, announced today the signing of an investment from KKR, a leading global investment firm. KKR will acquire a minority equity stake in Nordic Bioscience from existing shareholders and will support the company in accelerating its global growth.

Nordic Bioscience has world-leading knowledge and ownership of biomarkers, measurable indicators of biological change or response used for the development of diagnostic tools and identification of new drug candidates.

“KKR has a strong track record of supporting health care companies, and I look forward to leveraging KKR’s global network and experience across the pharma and wider drug development industry to accelerate the promising opportunities that we have to help improve the lives of patients with chronic diseases,” said Dr. Claus Christiansen, Founder & Chairman of Nordic Bioscience.

“We believe strongly in Nordic Bioscience’s vision to help patients globally by supporting the development of biomarkers and look forward to helping Nordic Bioscience achieve its ambitious plans for growth and international expansion,” said Kugan Sathiyanandarajah, Managing Director at KKR and Head of Europe for KKR’s Health Care Strategic Growth investing efforts, and Anuv Ratan, Principal at KKR.


Read More

Source: Business Wire